Healio

VIDEO: Tremfya maintains clinical, endoscopic efficacy through 3 years in Crohn’s disease

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio In a Healio video exclusive, Jan Wehkamp, ...
Seeking Alpha

TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years

*The as observed analysis set included participants who entered the LTE, received ≥1 partial or complete study drug dose during the LTE, remained on treatment, and had data available at Week 96; ...
Medical News Today

Tremfya for ulcerative colitis

Tremfya is a brand-name medication used to treat moderate to severe ulcerative colitis in adults by targeting a protein that reduces inflammation in the large intestine. Treatment with Tremfya ...
Seeking Alpha

TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

TREMFYA ® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease TREMFYA ® achieved significant rates of ...
Hosted on MSN

FDA Approves Johnson & Johnson’s Tremfya Subcutaneous Induction for Ulcerative Colitis

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved a subcutaneous induction regimen of TREMFYA (guselkumab) for the treatment of adults with ...
Healio

Tremfya’s FDA win as fully subcutaneous option for Crohn’s may pave way to eclipse Stelara

Please provide your email address to receive an email when new articles are posted on . Tremfya is the first approved IL-23 inhibitor to offer both IV and fully subcutaneous induction regimens. This ...